TERNS PHARMACEUTICALS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
TERNS PHARMACEUTICALS INC. - More news...
TERNS PHARMACEUTICALS INC. - More news...
- Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
- Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
- Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
- Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
- Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer
- Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
- Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
- Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
- Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501
- Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
- Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
- Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
- Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
- Terns Pharmaceuticals to Present at Upcoming Investor Conferences
- Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
- Terns Pharmaceuticals to Present at Upcoming Investor Conferences
- Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
- Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
- Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH
- Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series
- Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update
- Terns to Present at the 19th Annual Virtual Needham HealthCare Conference
- Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
- Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
- Terns to Present on VAP-1 and FXR at NASH-TAG Conference 2021
- Terns to Present at the Cowen 41st Annual Health Care Conference
